Source-grounded facts extracted from Sonoma Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Sonoma Pharmaceuticals, Inc. entered into Underwriting Agreement with Dawson James Securities, Inc. (effective 2026-04-24).
“On April 24, 2026, Sonoma Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Dawson James Securities, Inc. (the “Underwriter”).”
Sonoma Pharmaceuticals, Inc. entered into Manufacturing and Supply Agreement with Kenvue Brands LLC (effective 2025-10-24).
“On April 8, 2026, we entered into a Manufacturing and Supply Agreement with Kenvue Brands LLC for the sale of Microcyn ® technology-based products in the United States.”
Sonoma Pharmaceuticals, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“March 21, 2024, Sonoma Pharmaceuticals, Inc. (the “Company”) received a notice (the “Extension Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that Nasdaq granted the Company an additional 180 calendar days, or until September 16, 2024 to regain compliance with the minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2) (the “Rule”). The Extension Notice has no immediate effect on the listing of the Company’s common stock. As previously disclosed in the”
Sonoma Pharmaceuticals, Inc. amended Amendment No. 1 with Maxim Group LLC valued at up to $785,679 (effective 2024-03-08).
“On March 8, 2024, the Company entered into an amendment to the Agreement (“Amendment No. 1”) to provide for the sale of up to $785,679 of additional shares under the Agreement.”
Sonoma Pharmaceuticals, Inc. entered into a license with NovaBay Pharmaceuticals, Inc. (effective 2024-01-05).
“Effective January 5, 2024, Sonoma Pharmaceuticals, Inc. (the “Company”) entered into a license and distribution agreement with NovaBay Pharmaceuticals, Inc. for the sale and marketing of Avenova ® -branded products by the Company in the European Union.”
Sonoma Pharmaceuticals, Inc. entered into Equity Distribution Agreement with Maxim Group LLC valued at up to $392,077 (effective 2023-12-15).
“On December 15, 2023, Sonoma Pharmaceuticals, Inc. (the “Company”) entered into an Equity Distribution Agreement (the “Agreement”), with Maxim Group LLC (“Maxim”), pursuant to which the Company may offer and sell, from time to time, through Maxim, as sales agent or principal, shares of its common stock, $0.0001 par value per share.”
Sonoma Pharmaceuticals, Inc. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2023-09-28 meeting.
“Proposal 3 – Ratification of the Appointment of Independent Registered Public Accounting Firm Our stockholders voted upon and approved the ratification of the appointment of Frazier & Deeter, LLC as our independent registered public accounting firm for the fiscal year ending March 31, 2024. The votes on this proposal were as follows: FOR AGAINST ABSTAIN 2,560,351 41,495 3,765”
Sonoma Pharmaceuticals, Inc. shareholders rejected Advisory Vote to Approve Executive Compensation at the 2023-09-28 meeting.
“Proposal 2 – Advisory Vote to Approve Executive Compensation Our stockholders voted upon and did not approve, by non-binding advisory vote, the compensation of our named executive officers for the year ended March 31, 2023, as described in our proxy statement dated July 27, 2023. The votes on this proposal were as follows: FOR AGAINST ABSTAIN 560,065 290,657 8,188”
Sonoma Pharmaceuticals, Inc. shareholders approved Election of One Class III Director at the 2023-09-28 meeting.
“Proposal 1 – Election of One Class III Director Mr. Jerry McLaughlin was duly elected as our Class III director. The results of the election were as follows: NOMINEE FOR WITHHELD Jerry McLaughlin 552,672 306,238”
Sonoma Pharmaceuticals, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“September 22, 2023, we received a letter from the Listing Qualifications staff of The Nasdaq Stock Market LLC, notifying us that, for the previous 30 consecutive business days, we have failed to comply with Nasdaq Listing Rule 5550(a)(2), which requires us to maintain a minimum bid price of $1 per share for our common stock. In accordance with Listing Rule 5810(c)(3)(A), Nasdaq has granted us a period of 180 calendar days, or until March 20, 2024, to regain compliance with the Rule. We may regain compliance with the Rule at any time during this compliance period if the minimum bid price for ou”
John Dal Poggetto was appointed as Controller at Sonoma Pharmaceuticals, Inc..
“Effective July 17, 2023, our Board of Directors appointed John Dal Poggetto as our Controller.”
Jerry Dvonch was appointed as interim Chief Financial Officer at Sonoma Pharmaceuticals, Inc..
“Effective April 7, 2023, Chad White resigned as our Chief Financial Officer, and our Board of Directors appointed Jerry Dvonch as our interim Chief Financial Officer.”
Chad White resigned as Chief Financial Officer at Sonoma Pharmaceuticals, Inc..
“Effective April 7, 2023, Chad White resigned as our Chief Financial Officer, and our Board of Directors appointed Jerry Dvonch as our interim Chief Financial Officer.”
Sonoma Pharmaceuticals, Inc. amended At-The-Market Offering Agreement with Ladenburg Thalmann & Co. Inc. valued at aggregate offering amount increased to Maximum Amount; additional $420,838 (effective 2023-02-24).
“On February 24, 2023, we entered into an amendment (the “ATM Amendment”) to our At-The-Market Offering Agreement, dated December 23, 2022 (as amended by the ATM Amendment, the “Agreement”), with Ladenburg Thalmann & Co. Inc. Pursuant to the ATM Amendment, the aggregate offering amount of shares of the Company’s common stock, $0.0001 par value per share (the “Shares”), which the Company may sell and issue through Ladenburg, as the sales agent, was increased to the Maximum Amount as defined in the Agreement (the “ATM Upsize”).”
Sonoma Pharmaceuticals, Inc. entered into Exclusive Distribution Agreement with Daewoong Pharmaceutical Co., Ltd. valued at Exclusive distribution agreement for Primocyn Skin Solution products containing Microcyn technology (effective 2023-01-26).
“Effective January 26, 2023, we entered into an exclusive distribution agreement with Daewoong Pharmaceutical Co., Ltd. for the marketing and distribution of Primocyn TM Skin Solution products, containing our Microcyn® technology, in South Korea.”
Sonoma Pharmaceuticals, Inc. entered into At-The-Market Offering Agreement with Ladenburg Thalmann & Co. Inc. valued at aggregate offering price of up to $2,700,000 (effective 2022-12-23).
“On December 23, 2022, we entered into an At-The-Market Offering Agreement, or the ATM Agreement, with Ladenburg Thalmann & Co. Inc. , as sales agent, pursuant to which we may offer and sell, from time to time, through Ladenburg shares of our common stock, $0.0001 par value per share.”
Chad White changed role as Chief Financial Officer at Sonoma Pharmaceuticals, Inc..
“Effective November 18, 2022, Mr. White will serve as Chief Financial Officer of the Company.”
Chad White was appointed as Chief Financial Officer at Sonoma Pharmaceuticals, Inc..
“Effective on October 3, 2022, our Board of Directors appointed Chad White as our interim Chief Financial Officer.”
Jerry Dvonch resigned as Chief Financial Officer at Sonoma Pharmaceuticals, Inc..
“We accepted the resignation of Mr. Dvonch as Chief Financial Officer effective November 18, 2022.”
Jerry Dvonch resigned as Chief Financial Officer at Sonoma Pharmaceuticals, Inc..
“In connection with the Woodstock office closure, Mr. Jerry Dvonch resigned as our Chief Financial Officer.”
Amy Trombly was appointed as Director at Sonoma Pharmaceuticals, Inc..
“Effective July 22, 2022, the Company’s Board of Directors appointed Amy Trombly, our Chief Executive Officer, to serve as a member of our Board of Directors.”
Sharon Barbari departed as Director at Sonoma Pharmaceuticals, Inc..
“On July 27, 2021, Sharon Barbari, our director, chair of the audit committee and member of the compensation and nominating and corporate governance committee notified us that she does not intend to stand for re-election at out upcoming annual meeting of stockholders on September 15, 2021 due to personal reasons.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.